Today: 1 June 2026
BlackBerry heads for $10 again as QNX bet draws interest
1 June 2026
2 mins read

BlackBerry heads for $10 again as QNX bet draws interest

TORONTO, June 1, 2026, 12:06 EDT

  • BlackBerry’s U.S. shares climbed 7.8% to $9.70 late morning, with volume topping 25 million shares.
  • Toronto-listed shares hit a 52-week high at C$13.45. Canada’s main S&P/TSX Composite was down earlier in the session.

BlackBerry Ltd shares gained again Monday, nearing $10 in New York as investors continued to buy into the company’s software turnaround pitch.

The stock’s latest push higher stands out, as it isn’t driven by a new handset product. This time, the rise comes from QNX—BlackBerry’s embedded software arm—and its secure communications work with government and regulated clients.

BlackBerry shares trading in the U.S. gained 7.8% to $9.70 as of 11:51 a.m. EDT. The stock opened at $9.28 after closing at $9.00, then climbed as high as $9.74. BlackBerry’s market cap was about $5.77 billion.

Toronto outperformed on Monday. The S&P/TSX Composite was off 0.3% earlier in the day, dragged lower by financial and mining stocks, but BlackBerry’s Canadian shares jumped over 8% to reach a one-year high.

QNX is a real-time operating system, running tasks within tight time frames for cars, industrial systems, medical gear and other safety devices. BlackBerry investors have been re-rating this business as capital flows into robotics, “physical AI”—AI running in machines that do real-world work—and software-defined vehicles.

BlackBerry reported last week that a QNX poll of 1,000 robotics developers named software architecture and integration as the top performance bottlenecks, putting them ahead of hardware. Jim Hirsch, QNX’s global VP of sales for general embedded markets, said the same developers “consistently cite four core challenges: safety, determinism, cybersecurity, and integration.” Newswire

BlackBerry’s latest results have given the bulls something to work with. In April, the company said its QNX unit posted a 20% jump in fourth-quarter revenue to $78.7 million, with the royalty backlog hitting about $950 million. BlackBerry is also guiding for first-quarter revenue above Street forecasts. CEO John Giamatteo told Reuters the business delivers “highly regulated, complex, mission-critical solutions,” a phrase that has become a fixture in the bullish case for the stock. Reuters

BlackBerry’s competitive set is pretty focused. Investors aren’t really weighing it against old handset competitors. The real benchmark is other embedded and safety software firms, with Nvidia mostly showing up as a hardware AI partner. In April, QNX said it was expanding work with Nvidia to get its safety OS running on Nvidia IGX Thor, targeting robotics, medical, and industrial systems. “Safety and determinism cannot be afterthoughts,” QNX President John Wall said. Nasdaq

Security is in focus for traders too. BlackBerry said in May that its AtHoc platform finished FedRAMP Class D High re-certification. FedRAMP is the U.S. cloud security review program. Class D High covers sensitive unclassified systems where failure could hit operations or safety hard. Ramon Pinero, who heads secure communications at BlackBerry, called the re-certification proof of “operational maturity and security rigor.” Nasdaq

Capital return is in play too, but it’s a sideshow. In a May filing, BlackBerry said it renewed its normal course issuer bid—basically a Canadian buyback—giving it the option to repurchase up to 26.8 million common shares through May 2027.

The risk is clear. The stock outran what the business has shown so far. QNX backlog still needs to turn into revenue; robotics and automotive timing can shift, and government security deals are uneven. A rally driven by momentum could unwind fast if BlackBerry’s next quarter doesn’t deliver on software revenue and cash flow.

BlackBerry’s next test comes up soon. The company has June 25 marked on its investor calendar for its first-quarter fiscal 2027 results, which cover the stretch through May 31.

Stock Market Today

  • Bristol Myers Reports Positive Data on Multiple Myeloma and Lung Cancer Drugs at ASCO
    June 1, 2026, 12:28 PM EDT. Bristol Myers Squibb (BMY) presented phase III SUCCESSOR-2 trial results for mezigdomide, an oral CELMoD therapy for relapsed or refractory multiple myeloma (RRMM), at the 2026 ASCO meeting. Mezigdomide combined with carfilzomib and dexamethasone reduced disease progression or death risk by 52% versus standard treatment, with an 80.2% overall response rate. The safety profile showed increased Grade 3-4 adverse events such as neutropenia. Separately, BMY and BioNTech (BNTX) reported interim phase II data on pumitamig, a bispecific immunomodulator targeting PD-L1 and VEGF-A, plus chemotherapy in first-line advanced non-small cell lung cancer (NSCLC). The treatment showed high response rates and manageable safety. Development continues with phase III studies recruiting, highlighting BMY's expanding oncology pipeline.

Latest articles

BlackBerry heads for $10 again as QNX bet draws interest

BlackBerry heads for $10 again as QNX bet draws interest

1 June 2026
TORONTO, June 1, 2026, 12:06 EDT BlackBerry Ltd shares gained again Monday, nearing $10 in New York as investors continued to buy into the company’s software turnaround pitch. The stock’s latest push higher stands out, as it isn’t driven by a new handset product. This time, the rise comes from QNX—BlackBerry’s embedded software arm—and its secure communications work with government and regulated clients. BlackBerry shares trading in the U.S. gained 7.8% to $9.70 as of 11:51 a.m. EDT. The stock opened at $9.28 after closing at $9.00, then climbed as high as $9.74. BlackBerry’s market cap was about $5.77 billion.
UiPath Shares Jump Almost 10% as AI Test Arrives for PATH

UiPath Shares Jump Almost 10% as AI Test Arrives for PATH

1 June 2026
UiPath surged nearly 10% to $12.88 after Q1 revenue beat at $418M, guidance raised, and first GAAP profit posted. Annualized renewal run-rate climbed 12% to $1.901B. Analyst targets mostly unchanged; consensus neutral, average $14.48. BofA remains Underperform, citing AI competition and sustainability doubts. Microsoft and ServiceNow expanding in AI agents. UiPath warns on ARR risks, customer retention, and reliance on third-party AI models.
Rigetti Shares On The Move As Quantum Trade Faces Another Test

Rigetti Shares On The Move As Quantum Trade Faces Another Test

1 June 2026
Rigetti Computing jumped 3.4% to $26.41 after quantum error-correction research hit Nature Communications and investors reacted to last week’s U.S. funding news. Over 35 million shares traded before noon. Market cap neared $8.8 billion despite Q1 revenue of $4.4 million and a $26 million operating loss. The company signed a letter of intent for up to $100 million in CHIPS Act funding, with the government set to take an equity stake.
UiPath Shares Jump Almost 10% as AI Test Arrives for PATH
Previous Story

UiPath Shares Jump Almost 10% as AI Test Arrives for PATH

Go toTop